Close menu

June 9th, 2022 | 12:25 CEST

wallstreet:online, Alibaba, Novavax - Digital pioneers and old hands

  • Investments
  • neobroker
  • Biotechnology
Photo credits:

The number of young investors in Germany is rising steadily. To date, it stands at 49,000 people who are actively involved in their retirement planning. Both private and institutional investors are discovering the field of neobrokers as an investment. wallstreet:online AG is a candidate from the field with its own community. Alibaba founder Jack Ma has recognized that money has to keep moving in order to flow and is launching the first digital bank in Singapore. Things are somewhat more leisurely in the pharmaceutical sector: with Novavax, Americans now have four vaccines to choose from.

time to read: 4 minutes | Author: Juliane Zielonka

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    wallstreet:online - Good business with Smartbroker

    Around 12.1 million people in Germany own shares, equity funds and ETFs. One-third of equity savers are female, and 49,000 people under 30 have started investing, according to the Deutsches Aktieninstitut (DAI). While some investors used to have to go through the cumbersome process of calling and faxing in their stock orders, neobrokers now make buying and selling stocks a breeze. Meanwhile, investors can register with a new broker in less than fifteen minutes using digital online identity credentials and get started right away.

    **One of these neobrokers with a simultaneous newsfeed is wallstreet:online AG. The Group operates "Smartbroker" - an online broker that offers a comprehensive range of products at the conditions of a neobroker. In addition, the Group also provides its investors with financial news on various portals. With several hundred million monthly page impressions, the Group is the largest publisher-independent financial portal operator in the German-speaking world and maintains the largest financial community.

    The fact that neobrokers are in hot demand in the fintech scene is also evident at competitor Trade Republic. The non-listed company relies on strategic investors such as Sino AG and has just notarized a capital increase of around EUR 250 million. The new lead investor is the Ontario Teacher's Pension Plan ("OTPP"). In the 1980s, the government of Ontario, Canada, initiated intensive reforms to modernize the administration and investment of public pension plans. Out came the OTPP, which invests globally as a trustee and active investor. According to the press release, with the implementation of this expanded funding round, Sino's share will decrease to approximately 2.6% of Trade Republic's common stock.

    Alibaba - Advancing with digital bank in Singapore

    Finally, tech stocks from China are seeing bullish prices again. After the government dropped its investigation into the Chinese Uber, 'Didi', Alibaba's share price also jumped 4.8%. That is because Alibaba has invested there: Didi closed a EUR 4.2 billion funding round in June 2016 with investors including Apple Inc, China Life Insurance Co, and a financial subsidiary of Alibaba Group Holding Ltd. Didi Global went public in the US, last summer. But its stock price plummeted after China blocked the ride-sharing app. Last December, Didi said it wanted to delist from the US to go public in Hong Kong.

    Alibaba founder Jack Ma has been buzzing about his web of companies surrounding the international e-commerce conglomerate. His Ant Group is now launching a digital bank in Singapore. Named ANEXT, the digital bank will focus on serving local and regional micro, small and medium-sized enterprises ("SMEs"), especially those that operate across borders to expand globally, according to an Ant Group spokesperson. Anyone looking at Alibaba Group's business model will recognize the network of numerous merchants that use the Platform-as-a-Service to trade internationally. With ANEXT, payment flows remain in Jack Ma's sights as of now. Investors should look closely to see if the current Alibaba share price is a portfolio addition. The launch of the digital bank in Singapore is one of Ant Group's biggest ventures outside of China. Ant Group is a subsidiary of China's Alibaba Group. The Group owns China's largest digital payment platform, Alipay, which serves more than 1 billion users and 80 million merchants.

    Novavax - FDA recommends vaccine for US

    A panel of experts from the US Food and Drug Administration (FDA) has recommended the Novavax corona vaccine. Although the risk of heart muscle inflammation from the vaccination was pointed out in advance, the committee decided to approve it. Emergency approval for the vaccine is expected soon. This would be the fourth vaccine approved in the United States. After FDA clearance, it will then be the responsibility of the CDC to write the appropriate guidelines.

    The Novavax vaccine has been tested in two trials with nearly 45,000 participants and is used to combat the SARS-CoV-2 virus. The vaccine is already in use in the EU, Canada and the UK. The protein-based active ingredient is intended to convince people who are skeptical about an mRNA vaccination. The Company affirms that its active ingredient remains stable longer under refrigeration and is better tolerated than vaccines from Pfizer and consorts used on the market to date. Protein-based vaccines such as Novavax have been used in the pharmaceutical industry for years. They are used against influenza, hepatitis B and shingles. However, the timeline for development is longer. That is why the emergency approval of Novavax seems late from an investor's perspective.

    With just 49,000 Germans under the age of 30, both the Smartbroker product offers potential for further investor growth, as does the wallstreet:online AG share. They are the only ones in the German market to combine an online broker application with various financial news portals and an active investment community. Neobrokers seem so lucrative that even proven major investors such as Canada's Ontario Teacher's Pension Plan are investing in the market. Asian stocks are also picking up slightly. Alibaba founder Jack Ma is pulling off a coup outside China with his first digital bank, ANEXT, based in Singapore, to bundle payment flows for SMEs. Streams of Novavax will also soon be flowing into the veins of countless US residents who are getting vaccinated against COVID-19 with a protein-based vaccine. The FDA has given the green light for emergency approval. As a result, four vaccines are now available in the USA.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Juliane Zielonka

    Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.

    About the author

    Related comments:

    Commented by André Will-Laudien on February 20th, 2024 | 07:30 CET

    Takeover fever in the biotech sector! Will MorphoSys now be followed by Defence Therapeutics, Evotec and Bayer?

    • Biotechnology
    • Pharma
    • Innovations

    It has happened: Novartis is bidding for MorphoSys. Once again, a long-lasting and persistent rumour mill eventually confirms itself. Those who remained loyal to MorphoSys despite heavy selling last fall have now made a profit of over 300%. If we turn the analytical magnifying glass on the sector, we can see that the speculative biotech stock market segment has started to move again since the challenging year 2023. Hopes of falling interest rates in the near future, along with several other M&A hopes, have led to steady inflows into listed bio-ETFs, resulting in fund managers having recently adjusted their weightings upwards. We analyze which stocks are currently making the loudest noise.


    Commented by André Will-Laudien on February 16th, 2024 | 07:00 CET

    MorphoSys and Cardiol Therapeutics in upward mode, while Bayer and Pfizer are in slow mode

    • Biotechnology
    • Pharma

    The biotech sector has made a very differentiated start to the new year. While the old favorites are barely moving, the second-line stocks MorphoSys and Cardiol Therapeutics are making a real splash. At Bayer, the bad news just won't go away, and despite a successful major takeover, Pfizer has not yet found its forward gear. After a rally of almost 15% in December, the Nasdaq Biotechnology Index (NBI) has taken a pause in the current year. Now, everyone is waiting for the first interest rate cut by central banks. Inflation is already falling, and the negative economic data for the Eurozone is increasing. The ECB would normally be in demand. What should investors urgently keep an eye on?


    Commented by Armin Schulz on February 12th, 2024 | 07:00 CET

    MorphoSys, Defence Therapeutics, Bayer - Biotech and Pharma suddenly back in focus

    • Biotechnology
    • Pharma

    Biotech ETFs have been on the rise since the end of October 2023. German biotech companies were able to raise more funds again last year. There are increasing signs that the tough times for investors in biotech and pharmaceutical companies are over. There is also growing activity on the takeover side. Most recently, the takeover bid from Novartis shifted the focus to companies in the healthcare sector. The Swiss pharmaceutical company wants to acquire MorphoSys for EUR 2.7 billion and thus fill up its oncology pipeline. We have selected three companies from the biotech and pharma sectors and examined their current situation.